⚠ Evidence note: Most trends in this area rest on anecdote and mechanism; where real evidence exists it is usually for narrower claims than the trend makes.
GLP-1 Aesthetic Effects (Ozempic Face/Body)
Current understanding
To be populated as evidence accumulates.
Evidence log
- 2026-10-10 — “Ozempic Face” and Facial Aging.: 2026 clinical review synthesizes anatomy, presentation, and management of ‘Ozempic face’ — attributing the accelerated-aging look to rapid volume deflation, skin laxity, and loss of structural support, and framing dermatologic counseling and tissue-preservation strategies as the practice response; narrative synthesis, no new primary data. [expert-opinion] (novelty: 3)
- 2026-09-29 — Beyond Skin Laxity: GLP-1 Receptor Agonist-Induced Lean Mass Depletion and Surgical Tissue Quality in Aesthetic Surgery: A Narrative Review.: cross-connection with aoms-for-longevity: Lean-mass depletion on GLP-1 RAs (muscle-loss debate tracked under aoms-for-longevity) is now being linked to surgical tissue-quality concerns beyond the already-logged ‘Ozempic face/body’ skin-laxity phenotype — connecting the body-composition literature to the aesthetic-surgery trend. (novelty: 3)
- 2026-08-12 — Comparing Facial Aging Between Identical Twins With 3D Imaging: Planned identical-twin study with 3D facial imaging will include GLP-1 use as a candidate driver of within-pair facial-aging differences — first proposed design to quantify ‘Ozempic face’ against a genetically matched control, no readout yet. [human-observational] (novelty: 3)
- 2026-07-20 — Mapping the Impact of Glucagon-Like Peptide-1 Receptor Agonists on Aesthetic and Reconstructive Plastic Surgery: A Bibliometric Analysis of the 50 Most Cited Studies.: 2026 bibliometric analysis of the 50 most-cited GLP-1-in-plastic-surgery papers shows the field exploded in 2023–2025 around ‘Ozempic face,’ perioperative safety, and contouring after pharmacologic weight loss, but the highly cited work is largely narrative/descriptive rather than outcome-driven. [expert-opinion] (novelty: 3)
- 2026-08-03 — Anti-Obesity Medications in Longevity and Aesthetic Medicine.: Narrative review notes rapid AOM-driven weight loss drives soft-tissue laxity (‘Ozempic face/body’) alongside meaningful lean-mass loss, flagged as a foreseeable consequence of rate and magnitude of loss rather than a drug-specific dermal effect. [human-observational] (novelty: 3)
Open questions
Related
Contributing findings
"Ozempic Face" and Facial Aging.
10-oct-2026
novelty 3
per-area 3
strengthens
Comparing Facial Aging Between Identical Twins With 3D Imaging
12-aug-2026
novelty 3
per-area 3
strengthens
Anti-Obesity Medications in Longevity and Aesthetic Medicine.
03-aug-2026
novelty 3
per-area 3
strengthens
Mapping the Impact of Glucagon-Like Peptide-1 Receptor Agonists on Aesthetic and Reconstructive Plastic Surgery: A Bibliometric Analysis of the 50 Most Cited Studies.
20-jul-2026
novelty 3
per-area 3
strengthens